PDCD1 and melanoma: Similarly, a 2021 review detailing the treatment of advanced melanoma found a PD-1 blockade with BRAF/MEK inhibitor combination therapy demonstrated a 5-year overall survival benefit of 30–40% among melanoma patients [16].